{'fraction_non_alphanumeric': 0.04935622317596566, 'fraction_numerical': 0.03755364806866953, 'mean_word_length': 4.795031055900621, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Clinical evaluation of a single oral dose of human‐bovine (UK) reassortant rotavirus vaccines Wa x UK (P1A[8],G6) and Wa x (DS‐1 x UK) (P1A[8],G2)

The safety, infectivity, and immunogenicity of two human‐bovine reassortant rotavirus candidate vaccines were evaluated in adults, children, and infants. One of these, Wa x UK, contained a single human rotavirus gene from the Wa strain that encoded VP4 P1A specificity in a background of 10 bovine genes including the VP7 gene that encodes G6 specificity, whereas the other, Wa x (DS‐1 x UK), possessed the human rotavirus VP4 gene from the Wa strain as well as the human VP7 gene from strain DS‐1 that encoded G2 specificity. Each of these vaccines appeared to be well‐tolerated and immunogenic in infants less than 6 months of age following a single oral dose, and therefore should be evaluated further as vaccine candidates. J. Med. Virol. 66:407‐416, 2002. © 2002 Wiley‐Liss, Inc.